Pfizer may face lawsuits regarding improper marketing of Neurontin after a Boston court reinstated lawsuits that had been denied class-action status by lower courts. The court also upheld a $142.1 million award against Pfizer for damages related to the marketing of Neurontin.
Of further interest:
Court upholds $142 mln verdict against Pfizer over Neurontin (Reuters)
Pfizer fails to block $142M Neurontin award, faces 2 more suits (Fierce Pharma)
